Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in urogenital cancer

Akira Miyajima, Eiji Kikuchi, Takeo Kosaka, Mototsugu Oya

研究成果: Article査読

21 被引用数 (Scopus)

抄録

The potential for angiotensin II (AII) to promote tumor growth has been suspected based on its known hormonal actions and its vasoconstrictor effect. It has been suggested that angiotensin-converting enzyme (ACE) inhibitors may offer protection against cancer and may prevent carcinogenesis. Several studies report that AII can induce neovascularization in experimental systems by way of the AII type 1 receptor (AT1R). AT1R is also frequently expressed in such human tumors as skin cancer, renal cell carcinoma, and breast cancer. A growing number of recent studies focusing on treatment with an AT1R antagonist have demonstrated that angiotensin receptor blockade (ARB) appears to inhibit not only the growth of cancer cells but also tumor angiogenesis. We describe here the effects of AT1R blockade that implicate tumor angiogenesis in urogenital cancer since ARB may be an alternative modality for anti-cancer treatment.

本文言語English
ページ(範囲)75-78
ページ数4
ジャーナルReviews on Recent Clinical Trials
4
2
DOI
出版ステータスPublished - 2009 7月 30

ASJC Scopus subject areas

  • 薬理学

フィンガープリント

「Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in urogenital cancer」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル